阿伦膦酸盐降低骨质疏松性椎体骨折风险的作用  

The Effects of alendronate for reducing the risk of osteoporotic vertebral fracture

作　　者：贾璞[1] 唐海[1] 

机构地区：[1]首都医科大学附属北京友谊医院骨科,北京100050

出　　处：《中国骨质疏松杂志》2008年第8期591-595,542,共6页Chinese Journal of Osteoporosis

摘　　要：骨质疏松症已成为全球严重的公共卫生问题,防治骨质疏松症和骨质疏松性骨折已成为目前关注的课题。骨质疏松性骨折最常见于椎体。阿伦膦酸盐是临床上治疗骨质疏松症的常用药物。众多文献表明,阿伦膦酸盐能明显增加患者骨密度(BMD),使其发生椎体骨折和再骨折的危险性降低。与其他抗重吸收药物比较,阿伦膦酸盐增加BMD的作用较强。但目前尚未有文献对阿伦膦酸盐预防椎体强化术后椎体再骨折的疗效进行明确报道。Osteoporosis has became a serious public heahh problem in the world. Nowadays it has been paid closely attention to the prevention and treatment of osteoporosis and osteoporotic fracture. Alendronate is a common therapy to treat osteoporosis, which has an evident effect on increasing BMD, and reducing osteoporotic vertebral fractures and new fractures. Compared with other antiresorptive agents, alendronate has a stronger effect on increasing BMD. However, there is no strong evidence that alendronate could prevent adjacent vertebral fracture after vertebral augmentation.

关 键 词：阿伦膦酸盐 骨质疏松 椎体压缩骨折 再骨折 

分 类 号：R683.1[医药卫生—骨科学]